University Hospital and Clinics

BACKGROUND: An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab--which blocks cytotoxic T-lymphocyte-associated antigen 4 to potentiate an antitumor T-cell response--administered with or without a glycoprotein 100 (gp100) peptide vaccine was compared with gp100 alone in patients with previously treated metastatic melanoma. METHODS: A total of 676 HLA-A*0201-positive patients with unresectable stage III or IV melanoma, whose disease had progressed while they were receiving therapy for metastatic disease, were randomly assigned, in a 3:1:1 ratio, to receive ipilimumab plus gp100 (403 patients), ipilimumab alone (137), or gp100 alone (136). Ipilimumab, at a dose of 3 mg per kilogram of body weight, was administered with or without gp100 every 3 weeks for up to four treatments (induction). Eligible patients could receive reinduction therapy. The primary end point was overall survival. RESULTS: The median overall survival was 10.0 months among patients receiving ipilimumab plus gp100, as compared with 6.4 months among patients receiving gp100 alone (hazard ratio for death, 0.68; P<0.001). The median overall survival with ipilimumab alone was 10.1 months (hazard ratio for death in the comparison with gp100 alone, 0.66; P=0.003). No difference in overall survival was detected between the ipilimumab groups (hazard ratio with ipilimumab plus gp100, 1.04; P=0.76). Grade 3 or 4 immune-related adverse events occurred in 10 to 15% of patients treated with ipilimumab and in 3% treated with gp100 alone. There were 14 deaths related to the study drugs (2.1%), and 7 were associated with immune-related adverse events. CONCLUSIONS: Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma. Adverse events can be severe, long-lasting, or both, but most are reversible with appropriate treatment. (Funded by Medarex and Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00094653.)

BACKGROUND: Short-term preoperative radiotherapy and total mesorectal excision have each been shown to improve local control of disease in patients with resectable rectal cancer. We conducted a multicenter, randomized trial to determine whether the addition of preoperative radiotherapy increases the benefit of total mesorectal excision. METHODS: We randomly assigned 1861 patients with resectable rectal cancer either to preoperative radiotherapy (5 Gy on each of five days) followed by total mesorectal excision (924 patients) or to total mesorectal excision alone (937 patients). The trial was conducted with the use of standardization and quality-control measures to ensure the consistency of the radiotherapy, surgery, and pathological techniques. RESULTS: Of the 1861 patients randomly assigned to one of the two treatment groups, 1805 were eligible to participate. The overall rate of survival at two years among the eligible patients was 82.0 percent in the group assigned to both radiotherapy and surgery and 81.8 percent in the group assigned to surgery alone (P=0.84). Among the 1748 patients who underwent a macroscopically complete local resection, the rate of local recurrence at two years was 5.3 percent. The rate of local recurrence at two years was 2.4 percent in the radiotherapy-plus-surgery group and 8.2 percent in the surgery-only group (P<0.001). CONCLUSIONS: Short-term preoperative radiotherapy reduces the risk of local recurrence in patients with rectal cancer who undergo a standardized total mesorectal excision.

The objective of this study was to determine whether endogenous nitric oxide (NO) inhibits leukocyte adhesion to vascular endothelium. This was accomplished by superfusing a cat mesenteric preparation with inhibitors of NO production, NG-monomethyl-L-arginine (L-NMMA) or NG-nitro-L-arginine methyl ester (L-NAME), and observing single (30-microns diameter) venules by intravital video microscopy. Thirty minutes into the superfusion period the number of adherent and emigrated leukocytes, the erythrocyte velocity, and the venular diameter were measured; venular blood flow and shear rate were calculated from the measured parameters. The contribution of the leukocyte adhesion glycoprotein CD11/CD18 was determined using the CD18-specific monoclonal antibody IB4. Both inhibitors of NO production increased leukocyte adherence more than 15-fold. Leukocyte emigration was also enhanced, whereas venular shear rate was reduced by nearly half. Antibody IB4 abolished the leukocyte adhesion induced by L-NMMA and L-NAME. Incubation of isolated cat neutrophils with L-NMMA, but not L-NAME, resulted in direct upregulation of CD11/CD18 as assessed by flow cytometry. Decrements in venular shear rate induced by partial occlusion of the superior mesenteric artery in untreated animals revealed that only a minor component of L-NAME-induced leukocyte adhesion was shear rate-dependent. The L-NAME-induced adhesion was inhibited by L-arginine but not D-arginine. These data suggest that endothelium-derived NO may be an important endogenous modulator of leukocyte adherence and that impairment of NO production results in a pattern of leukocyte adhesion and emigration that is characteristic of acute inflammation.

BACKGROUND: Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. We evaluated this agent in patients who had not received previous chemotherapy. METHODS: In this double-blind study, we randomly assigned 1088 patients to receive abiraterone acetate (1000 mg) plus prednisone (5 mg twice daily) or placebo plus prednisone. The coprimary end points were radiographic progression-free survival and overall survival. RESULTS: The study was unblinded after a planned interim analysis that was performed after 43% of the expected deaths had occurred. The median radiographic progression-free survival was 16.5 months with abiraterone-prednisone and 8.3 months with prednisone alone (hazard ratio for abiraterone-prednisone vs. prednisone alone, 0.53; 95% confidence interval [CI], 0.45 to 0.62; P<0.001). Over a median follow-up period of 22.2 months, overall survival was improved with abiraterone-prednisone (median not reached, vs. 27.2 months for prednisone alone; hazard ratio, 0.75; 95% CI, 0.61 to 0.93; P=0.01) but did not cross the efficacy boundary. Abiraterone-prednisone showed superiority over prednisone alone with respect to time to initiation of cytotoxic chemotherapy, opiate use for cancer-related pain, prostate-specific antigen progression, and decline in performance status. Grade 3 or 4 mineralocorticoid-related adverse events and abnormalities on liver-function testing were more common with abiraterone-prednisone. CONCLUSIONS: Abiraterone improved radiographic progression-free survival, showed a trend toward improved overall survival, and significantly delayed clinical decline and initiation of chemotherapy in patients with metastatic castration-resistant prostate cancer. (Funded by Janssen Research and Development, formerly Cougar Biotechnology; ClinicalTrials.gov number, NCT00887198.).

PURPOSE: The development of computer-aided diagnostic (CAD) methods for lung nodule detection, classification, and quantitative assessment can be facilitated through a well-characterized repository of computed tomography (CT) scans. The Lung Image Database Consortium (LIDC) and Image Database Resource Initiative (IDRI) completed such a database, establishing a publicly available reference for the medical imaging research community. Initiated by the National Cancer Institute (NCI), further advanced by the Foundation for the National Institutes of Health (FNIH), and accompanied by the Food and Drug Administration (FDA) through active participation, this public-private partnership demonstrates the success of a consortium founded on a consensus-based process. METHODS: Seven academic centers and eight medical imaging companies collaborated to identify, address, and resolve challenging organizational, technical, and clinical issues to provide a solid foundation for a robust database. The LIDC/IDRI Database contains 1018 cases, each of which includes images from a clinical thoracic CT scan and an associated XML file that records the results of a two-phase image annotation process performed by four experienced thoracic radiologists. In the initial blinded-read phase, each radiologist independently reviewed each CT scan and marked lesions belonging to one of three categories ("nodule > or =3 mm," "nodule <3 mm," and "non-nodule > or =3 mm"). In the subsequent unblinded-read phase, each radiologist independently reviewed their own marks along with the anonymized marks of the three other radiologists to render a final opinion. The goal of this process was to identify as completely as possible all lung nodules in each CT scan without requiring forced consensus. RESULTS: The Database contains 7371 lesions marked "nodule" by at least one radiologist. 2669 of these lesions were marked "nodule > or =3 mm" by at least one radiologist, of which 928 (34.7%) received such marks from all four radiologists. These 2669 lesions include nodule outlines and subjective nodule characteristic ratings. CONCLUSIONS: The LIDC/IDRI Database is expected to provide an essential medical imaging research resource to spur CAD development, validation, and dissemination in clinical practice.

The success of the Apgar score demonstrates the astounding power of an appropriate clinical instrument. This down-to-earth book provides practical advice, underpinned by theoretical principles, on developing and evaluating measurement instruments in all fields of medicine. It equips you to choose the most appropriate instrument for specific purposes. The book covers measurement theories, methods and criteria for evaluating and selecting instruments. It provides methods to assess measurement properties, such as reliability, validity and responsiveness, and interpret the results. Worked examples and end-of-chapter assignments use real data and well-known instruments to build your skills at implementation and interpretation through hands-on analysis of real-life cases. All data and solutions are available online. This is a perfect course book for students and a perfect companion for professionals/researchers in the medical and health sciences who care about the quality and meaning of the measurements they perform.

BACKGROUND: Activating mutations in serine-threonine protein kinase B-RAF (BRAF) are found in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy improves survival, as compared with chemotherapy, but responses are often short-lived. In previous trials, MEK inhibition appeared to be promising in this population. METHODS: In this phase 3 open-label trial, we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation to receive either trametinib, an oral selective MEK inhibitor, or chemotherapy in a 2:1 ratio. Patients received trametinib (2 mg orally) once daily or intravenous dacarbazine (1000 mg per square meter of body-surface area) or paclitaxel (175 mg per square meter) every 3 weeks. Patients in the chemotherapy group who had disease progression were permitted to cross over to receive trametinib. Progression-free survival was the primary end point, and overall survival was a secondary end point. RESULTS: Median progression-free survival was 4.8 months in the trametinib group and 1.5 months in the chemotherapy group (hazard ratio for disease progression or death in the trametinib group, 0.45; 95% confidence interval [CI], 0.33 to 0.63; P<0.001). At 6 months, the rate of overall survival was 81% in the trametinib group and 67% in the chemotherapy group despite crossover (hazard ratio for death, 0.54; 95% CI, 0.32 to 0.92; P=0.01). Rash, diarrhea, and peripheral edema were the most common toxic effects in the trametinib group and were managed with dose interruption and dose reduction; asymptomatic and reversible reduction in the cardiac ejection fraction and ocular toxic effects occurred infrequently. Secondary skin neoplasms were not observed. CONCLUSIONS: Trametinib, as compared with chemotherapy, improved rates of progression-free and overall survival among patients who had metastatic melanoma with a BRAF V600E or V600K mutation. (Funded by GlaxoSmithKline; METRIC ClinicalTrials.gov number, NCT01245062.).

Fluorescence microscopy is one of the most powerful tools for elucidating the cellular functions of proteins and other molecules. In many cases, the function of a molecule can be inferred from its association with specific intracellular compartments or molecular complexes, which is typically determined by comparing the distribution of a fluorescently labeled version of the molecule with that of a second, complementarily labeled probe. Although arguably the most common application of fluorescence microscopy in biomedical research, studies evaluating the "colocalization" of two probes are seldom quantified, despite a diversity of image analysis tools that have been specifically developed for that purpose. Here we provide a guide to analyzing colocalization in cell biology studies, emphasizing practical application of quantitative tools that are now widely available in commercial and free image analysis software.

BACKGROUND: Evidence from a recent trial has shown that the antiinflammatory effects of colchicine reduce the risk of cardiovascular events in patients with recent myocardial infarction, but evidence of such a risk reduction in patients with chronic coronary disease is limited. METHODS: In a randomized, controlled, double-blind trial, we assigned patients with chronic coronary disease to receive 0.5 mg of colchicine once daily or matching placebo. The primary end point was a composite of cardiovascular death, spontaneous (nonprocedural) myocardial infarction, ischemic stroke, or ischemia-driven coronary revascularization. The key secondary end point was a composite of cardiovascular death, spontaneous myocardial infarction, or ischemic stroke. RESULTS: A total of 5522 patients underwent randomization; 2762 were assigned to the colchicine group and 2760 to the placebo group. The median duration of follow-up was 28.6 months. A primary end-point event occurred in 187 patients (6.8%) in the colchicine group and in 264 patients (9.6%) in the placebo group (incidence, 2.5 vs. 3.6 events per 100 person-years; hazard ratio, 0.69; 95% confidence interval [CI], 0.57 to 0.83; P<0.001). A key secondary end-point event occurred in 115 patients (4.2%) in the colchicine group and in 157 patients (5.7%) in the placebo group (incidence, 1.5 vs. 2.1 events per 100 person-years; hazard ratio, 0.72; 95% CI, 0.57 to 0.92; P = 0.007). The incidence rates of spontaneous myocardial infarction or ischemia-driven coronary revascularization (composite end point), cardiovascular death or spontaneous myocardial infarction (composite end point), ischemia-driven coronary revascularization, and spontaneous myocardial infarction were also significantly lower with colchicine than with placebo. The incidence of death from noncardiovascular causes was higher in the colchicine group than in the placebo group (incidence, 0.7 vs. 0.5 events per 100 person-years; hazard ratio, 1.51; 95% CI, 0.99 to 2.31). CONCLUSIONS: In a randomized trial involving patients with chronic coronary disease, the risk of cardiovascular events was significantly lower among those who received 0.5 mg of colchicine once daily than among those who received placebo. (Funded by the National Health Medical Research Council of Australia and others; LoDoCo2 Australian New Zealand Clinical Trials Registry number, ACTRN12614000093684.).

During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. To date, very little evidence is established on this "silent" stage of the disease. A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage. This article is aimed at addressing all the different issues by providing for each of them an updated review of the literature and evidence, with practical recommendations.

BACKGROUND: The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to prolong progression-free and overall survival among patients with advanced melanoma. We conducted a phase 3 double-blind trial to evaluate pembrolizumab as adjuvant therapy in patients with resected, high-risk stage III melanoma. METHODS: Patients with completely resected stage III melanoma were randomly assigned (with stratification according to cancer stage and geographic region) to receive 200 mg of pembrolizumab (514 patients) or placebo (505 patients) intravenously every 3 weeks for a total of 18 doses (approximately 1 year) or until disease recurrence or unacceptable toxic effects occurred. Recurrence-free survival in the overall intention-to-treat population and in the subgroup of patients with cancer that was positive for the PD-1 ligand (PD-L1) were the primary end points. Safety was also evaluated. RESULTS: At a median follow-up of 15 months, pembrolizumab was associated with significantly longer recurrence-free survival than placebo in the overall intention-to-treat population (1-year rate of recurrence-free survival, 75.4% [95% confidence interval {CI}, 71.3 to 78.9] vs. 61.0% [95% CI, 56.5 to 65.1]; hazard ratio for recurrence or death, 0.57; 98.4% CI, 0.43 to 0.74; P<0.001) and in the subgroup of 853 patients with PD-L1-positive tumors (1-year rate of recurrence-free survival, 77.1% [95% CI, 72.7 to 80.9] in the pembrolizumab group and 62.6% [95% CI, 57.7 to 67.0] in the placebo group; hazard ratio, 0.54; 95% CI, 0.42 to 0.69; P<0.001). Adverse events of grades 3 to 5 that were related to the trial regimen were reported in 14.7% of the patients in the pembrolizumab group and in 3.4% of patients in the placebo group. There was one treatment-related death due to myositis in the pembrolizumab group. CONCLUSIONS: As adjuvant therapy for high-risk stage III melanoma, 200 mg of pembrolizumab administered every 3 weeks for up to 1 year resulted in significantly longer recurrence-free survival than placebo, with no new toxic effects identified. (Funded by Merck; ClinicalTrials.gov number, NCT02362594 ; EudraCT number, 2014-004944-37 .).

BACKGROUND: The value of regular surveillance for breast cancer in women with a genetic or familial predisposition to breast cancer is currently unproven. We compared the efficacy of magnetic resonance imaging (MRI) with that of mammography for screening in this group of high-risk women. METHODS: Women who had a cumulative lifetime risk of breast cancer of 15 percent or more were screened every six months with a clinical breast examination and once a year by mammography and MRI, with independent readings. The characteristics of the cancers that were detected were compared with the characteristics of those in two different age-matched control groups. RESULTS: We screened 1909 eligible women, including 358 carriers of germ-line mutations. Within a median follow-up period of 2.9 years, 51 tumors (44 invasive cancers, 6 ductal carcinomas in situ, and 1 lymphoma) and 1 lobular carcinoma in situ were detected. The sensitivity of clinical breast examination, mammography, and MRI for detecting invasive breast cancer was 17.9 percent, 33.3 percent, and 79.5 percent, respectively, and the specificity was 98.1 percent, 95.0 percent, and 89.8 percent, respectively. The overall discriminating capacity of MRI was significantly better than that of mammography (P<0.05). The proportion of invasive tumors that were 10 mm or less in diameter was significantly greater in our surveillance group (43.2 percent) than in either control group (14.0 percent [P<0.001] and 12.5 percent [P=0.04], respectively). The combined incidence of positive axillary nodes and micrometastases in invasive cancers in our study was 21.4 percent, as compared with 52.4 percent (P<0.001) and 56.4 percent (P=0.001) in the two control groups. CONCLUSIONS: MRI appears to be more sensitive than mammography in detecting tumors in women with an inherited susceptibility to breast cancer.

BACKGROUND: The role of fibrinolytic therapy in patients with intermediate-risk pulmonary embolism is controversial. METHODS: In a randomized, double-blind trial, we compared tenecteplase plus heparin with placebo plus heparin in normotensive patients with intermediate-risk pulmonary embolism. Eligible patients had right ventricular dysfunction on echocardiography or computed tomography, as well as myocardial injury as indicated by a positive test for cardiac troponin I or troponin T. The primary outcome was death or hemodynamic decompensation (or collapse) within 7 days after randomization. The main safety outcomes were major extracranial bleeding and ischemic or hemorrhagic stroke within 7 days after randomization. RESULTS: Of 1006 patients who underwent randomization, 1005 were included in the intention-to-treat analysis. Death or hemodynamic decompensation occurred in 13 of 506 patients (2.6%) in the tenecteplase group as compared with 28 of 499 (5.6%) in the placebo group (odds ratio, 0.44; 95% confidence interval, 0.23 to 0.87; P=0.02). Between randomization and day 7, a total of 6 patients (1.2%) in the tenecteplase group and 9 (1.8%) in the placebo group died (P=0.42). Extracranial bleeding occurred in 32 patients (6.3%) in the tenecteplase group and 6 patients (1.2%) in the placebo group (P<0.001). Stroke occurred in 12 patients (2.4%) in the tenecteplase group and was hemorrhagic in 10 patients; 1 patient (0.2%) in the placebo group had a stroke, which was hemorrhagic (P=0.003). By day 30, a total of 12 patients (2.4%) in the tenecteplase group and 16 patients (3.2%) in the placebo group had died (P=0.42). CONCLUSIONS: In patients with intermediate-risk pulmonary embolism, fibrinolytic therapy prevented hemodynamic decompensation but increased the risk of major hemorrhage and stroke. (Funded by the Programme Hospitalier de Recherche Clinique in France and others; PEITHO EudraCT number, 2006-005328-18; ClinicalTrials.gov number, NCT00639743.).

BACKGROUND: Laparoscopic resection of colorectal cancer is widely used. However, robust evidence to conclude that laparoscopic surgery and open surgery have similar outcomes in rectal cancer is lacking. A trial was designed to compare 3-year rates of cancer recurrence in the pelvic or perineal area (locoregional recurrence) and survival after laparoscopic and open resection of rectal cancer. METHODS: In this international trial conducted in 30 hospitals, we randomly assigned patients with a solitary adenocarcinoma of the rectum within 15 cm of the anal verge, not invading adjacent tissues, and without distant metastases to undergo either laparoscopic or open surgery in a 2:1 ratio. The primary end point was locoregional recurrence 3 years after the index surgery. Secondary end points included disease-free and overall survival. RESULTS: A total of 1044 patients were included (699 in the laparoscopic-surgery group and 345 in the open-surgery group). At 3 years, the locoregional recurrence rate was 5.0% in the two groups (difference, 0 percentage points; 90% confidence interval [CI], -2.6 to 2.6). Disease-free survival rates were 74.8% in the laparoscopic-surgery group and 70.8% in the open-surgery group (difference, 4.0 percentage points; 95% CI, -1.9 to 9.9). Overall survival rates were 86.7% in the laparoscopic-surgery group and 83.6% in the open-surgery group (difference, 3.1 percentage points; 95% CI, -1.6 to 7.8). CONCLUSIONS: Laparoscopic surgery in patients with rectal cancer was associated with rates of locoregional recurrence and disease-free and overall survival similar to those for open surgery. (Funded by Ethicon Endo-Surgery Europe and others; COLOR II ClinicalTrials.gov number, NCT00297791.).

OBJECTIVE: To evaluate the efficacy and safety of rituximab in a randomized, double-blind, placebo-controlled phase III trial in patients with lupus nephritis treated concomitantly with mycophenolate mofetil (MMF) and corticosteroids. METHODS: Patients (n = 144) with class III or class IV lupus nephritis were randomized 1:1 to receive rituximab (1,000 mg) or placebo on days 1, 15, 168, and 182. The primary end point was renal response status at week 52. RESULTS: Rituximab depleted peripheral CD19+ B cells in 71 of 72 patients. The overall (complete and partial) renal response rates were 45.8% among the 72 patients receiving placebo and 56.9% among the 72 patients receiving rituximab (P = 0.18); partial responses accounted for most of the difference. The primary end point (superior response rate with rituximab) was not achieved. Eight placebo-treated patients and no rituximab-treated patients required cyclophosphamide rescue therapy through week 52. Statistically significant improvements in serum complement C3, C4, and anti-double-stranded DNA (anti-dsDNA) levels were observed among patients treated with rituximab. In both treatment groups, a reduction in anti-dsDNA levels greater than the median reduction was associated with reduced proteinuria. The rates of serious adverse events, including infections, were similar in both groups. Neutropenia, leukopenia, and hypotension occurred more frequently in the rituximab group. CONCLUSION: Although rituximab therapy led to more responders and greater reductions in anti-dsDNA and C3/C4 levels, it did not improve clinical outcomes after 1 year of treatment. The combination of rituximab with MMF and corticosteroids did not result in any new or unexpected safety signals.

This document is the first update of the American College of Gastroenterology (ACG) colorectal cancer (CRC) screening recommendations since 2000. The CRC screening tests are now grouped into cancer prevention tests and cancer detection tests. Colonoscopy every 10 years, beginning at age 50, remains the preferred CRC screening strategy. It is recognized that colonoscopy is not available in every clinical setting because of economic limitations. It is also realized that not all eligible persons are willing to undergo colonoscopy for screening purposes. In these cases, patients should be offered an alternative CRC prevention test (flexible sigmoidoscopy every 5-10 years, or a computed tomography (CT) colonography every 5 years) or a cancer detection test (fecal immunochemical test for blood, FIT).

This guideline has been approved by the American Association for the Study of Liver Diseases (AASLD) and represents the position of the association. These recommendations provide a data-supported approach to the diagnosis and treatment of patients with Wilson disease. They are based on the following: (1) formal review and analysis of the recently-published world literature on the topic including Medline search; (2) American College of Physicians Manual for Assessing Health Practices and Designing Practice Guidelines1; (3) guideline policies, including the AASLD Policy on the Development and Use of Practice Guidelines and the American Gastroenterological Association Policy Statement on Guidelines2; (4) the experience of the authors in the specified topic. A significant problem with the literature on Wilson disease is that patients are sufficiently rare to preclude large cohort studies or randomized controlled trials; moreover, most treatment modalities were developed at a time when conventions for drug assessment were less stringent than at present. Intended for use by physicians, these recommendations suggest preferred approaches to the diagnostic, therapeutic, and preventive aspects of care. They are intended to be flexible, in contrast to standards of care, which are inflexible policies to be followed in every case. Specific recommendations are based on relevant published information. To characterize more fully the quality of evidence supporting recommendations, the Practice Guidelines Committee of the AASLD requires a class (reflecting benefit versus risk) and level (assessing strength or certainty) of evidence to be assigned and reported with each recommendation (Table 1, adapted from the American College of Cardiology and the American Heart Association Practice Guidelines3, 4). AASLD, American Association for the Study of Liver Diseases; BAL, British anti-Lewisite; MR, magnetic resonance; TM, tetrathiomolybdate; WD, Wilson disease. Copper is an essential metal that is an important cofactor for many proteins. The average diet provides substantial amounts of copper, typically 2-5 mg/day; the recommended intake is 0.9 mg/day. Most dietary copper ends up being excreted. Copper is absorbed by enterocytes mainly in the duodenum and proximal small intestine and transported in the portal circulation in association with albumin and the amino acid histidine to the liver, where it is avidly removed from the circulation. The liver utilizes some copper for metabolic needs, synthesizes and secretes the copper-containing protein ceruloplasmin, and excretes excess copper into bile. Processes that impair biliary copper excretion can lead to increases in hepatic copper content. Wilson disease (WD; also known as hepatolenticular degeneration) was first described in 1912 by Kinnear Wilson as “progressive lenticular degeneration,” a familial, lethal neurological disease accompanied by chronic liver disease leading to cirrhosis.5 Over the next several decades, the role of copper in the pathogenesis of WD was established, and the pattern of inheritance was determined to be autosomal recessive.6, 7 In 1993, the abnormal gene in WD was identified.8-10 This gene, ATP7B, encodes a metal-transporting P-type adenosine triphosphatase (ATPase), which is expressed mainly in hepatocytes and functions in the transmembrane transport of copper within hepatocytes. Absent or reduced function of ATP7B protein leads to decreased hepatocellular excretion of copper into bile. This results in hepatic copper accumulation and injury. Eventually, copper is released into the bloodstream and deposited in other organs, notably the brain, kidneys, and cornea. Failure to incorporate copper into is an of the of ATP7B The hepatic and of the protein copper, in the decreased level of in most patients with WD to the reduced of WD with an average of can as liver as a neurological being less or or as WD with liver disease more in and patients than in at are WD was were developed a WD was of the first liver for which treatment was The first in for the treatment of WD was British or The and of an by in treatment of treatment modalities been including to copper to copper and and liver which be and for Over the more of to WD to of These of of reduced of in the circulation of most and the to copper in liver studies it to of or of ATP7B which are for of of patients or to for ATP7B on of with neurological and are as WD the The with liver is at with a decreased and has been as of the patients with liver disease of these and a in to the as with other liver patients to when disease is at diagnosis is and a of and is to the diagnosis of WD A has been to based on a of it has been to in A analysis or analysis be in of to diagnosis of Wilson disease in a with liver disease. for or of to or or that for The of liver disease in patients with WD is in The of the liver disease can be from with to liver be with hepatic or abnormal patients a an and with from with or of on liver patients with of chronic liver disease and evidence of or with to with portal WD also as liver with an and patients of to be with WD when liver disease is In was a in of in these as a or was and In a of of WD, with of the patients with also with WD a of an of with in or in with a of that to be for WD and be in of WD typically than the liver most in the of can in in including in in or to and small as in disease in with disease of and of also with a of be present. and be are with other and of the with or are from liver disease. to diagnosis of Wilson disease in a with a neurological or disease with or liver disease. for or to or or with WD with important from or including and as and and or when are the at which WD or be is and than the and WD is in than with in in a and liver in a The patients with WD, by studies ATP7B were in the for of WD is as when other or and or suggest be in of copper in of the cornea. are by as a of the A by an is to in most They are for WD, be in patients with chronic and in with these can be from WD on of patients with WD that are in of patients with mainly hepatic disease at the time of In with liver are are in patients with a neurological in these patients be in of are reported with chronic liver disease. be also by of copper in the These typically and with treatment or liver the of with of The of of these in a in these with WD be in the of and with liver of be the for a diagnosis of WD WD be in with liver disease with neurological or In a in WD is be by by a The of the diagnosis of WD, in patients with neurological disease are abnormal in WD at a In many the of of be and the of the liver disease. This protein is mainly in the liver and is an The of the protein is into the circulation from hepatocytes as a protein copper of and the as the protein copper is the for copper in the for of the copper in is a is a and it as an for as and which the for for the of be by these or by as or are as in use and This as a to are by and in with as and use of some of are in to the of at than in and to the is typically decreased in patients with WD, be in other with or protein or with liver disease of or with rare of of been in patients with copper when were to and in patients with an of copper transport to in with the rare the protein to in the gene on these patients copper A level are on the has been with WD, and with A of as a for WD in patients with liver disease that a of patients and of these was to the of for In of patients with WD and In of patients with WD and of In of patients and in an of with WD most based on several of experience from the that of patients in the to patients with WD is by with some of decreased of acid be decreased at with hepatic or neurological disease of evidence is to the of level or be as evidence for the diagnosis of suggest is within the the diagnosis a disease of copper the copper copper in in WD is decreased in to the decreased in the circulation. In patients with liver copper be within the a decreased In the of liver to WD, of copper be to the of the metal from or copper in the of decreased of an in the of copper to in the The copper has been as a for is in most patients or copper is from the copper and The of copper with is of copper of the copper is the the copper in and the in copper and be expressed as the is the is The copper be in liver of in and it be in chronic and in of copper from or The problem with copper as a for WD is that it is on the of the for copper and the copper is more the the copper be it be a This be of more in of than in the diagnosis of copper copper that can in some patients with The of copper in the in a be for WD and for of The excretion of copper the of copper in the circulation. can provide as copper the and the is is in the copper in for to be and excretion in the are to The level as of WD is in studies that copper excretion be at in of patients with The for excretion of copper as the of This to be a for copper excretion can be to with in other of liver and also with chronic liver including copper excretion in the of In of patients with chronic liver of patients copper excretion has also been reported in with copper excretion with be a This has been in a in which of was at the and the of to a of other liver including and liver a was when was excreted. of the in it for the diagnosis of WD in patients with liver disease for the diagnosis in the of the to be This has been in many of the reported results of in and for of of the excretion of copper of the assessment to for WD, it has been as the for excretion of copper be in patients in the diagnosis of WD is being The of copper in the is typically in or WD and requires studies be for the of evidence for the diagnosis of WD in copper excretion is for the of the of of at the and the are in patients with Wilson disease. The of in is copper the evidence for has been as being and based on based on analysis of a of has been to with some of In large patients at and of The of hepatic copper in In hepatic copper also be of hepatic copper also be in copper as for copper be with a or and in a A of a of liver be in a and for to a for copper can also be for copper content. The problem with hepatic copper is that in of WD, of copper within the liver is In copper are next to with the can be to In a was sufficiently to in patients with and In the of is with at of be for with a liver in a with or been by the of the liver the of hepatic copper is most important in patients in hepatocellular copper is mainly and by In patients with WD a ceruloplasmin, into protein is reduced with and most The to incorporate copper into the protein within the in with the disease. This is of the in to is the use of a for copper which can be by has in from patients and is copper provides and be in where the diagnosis is and in In hepatic copper a diagnosis of is for patients with copper is liver disease or other of WD The in the liver and in and hepatocellular The liver of and is in most patients by the of is are some to hepatic is In the of liver to WD, is hepatocellular and typically on the of of hepatocytes is a with liver to of copper in hepatocytes by is In of the copper is mainly in the to and is in copper is in The of copper from to in liver and from to in The of copper WD, and has a for for protein can be by including the or The more for copper protein is analysis of liver at the time is Specific of be in and of the and including and which be The most is with of the of the a In the of these are to be of these of the within are present. analysis be a for diagnosis in to and it requires that of the is in the when is Development of hepatocellular was as rare with WD, suggest it in WD more than A of WD has been for hepatocellular has been recommended for patients with of in to be at for with at the time of disease as with of and or with and which can lead to and and patients with or of magnetic of the or in the Most are on and on in the of the be more in these are to and other been on be in some to the of be on patients with with a or be for of patients with treatment or treatment is A based on that for disease was to patients with WD in trials; has been of and of the brain, by be to treatment in patients with WD and be of the of with neurological with WD studies are for analysis based on the WD gene is from This analysis requires the of a within the by and studies as the or based on the pattern of and ATP7B, is determined in the the of the from can be to are or can also be has diagnosis in for analysis is of results can be most patients are with a on each more than of ATP7B been gene been as disease for analysis is an for a of ATP7B with a and in the are in as in the in also of the in WD are by the of and the of in suggest that of the including or the lead to of hepatic is to In analysis by is and be on in the diagnosis is to by and analysis or for known can be for of of patients with A be to the results with WD, and on liver from with and with the diagnosis of to and to treatment be for patients with WD benefit from a of treatment with with treatment for In some patients WD and be in WD is as as in liver disease patients with WD or with of to to in from the of or of A level of is essential for the of patients with liver to WD from with liver to or drug The of in most of these with liver of other leads to an of the of the disease. is the of in the of liver is copper and excretion of copper are The copper is or In many these results are in a and diagnosis has to on be to the diagnosis of WD be in of these as are suggest to diagnosis is important these patients liver to In some patients with liver to WD, the level be than the is sufficiently to be A more in is the level of and a of to of A to be at the time of diagnosis of liver to WD that be to liver has been developed based on and of it it and in patients with disease. This has been and and provide a more is the first of WD in the liver disease is is typically is that an as a or drug liver disease. patients liver from and are at that time to with liver to WD are the of for liver by the for the of the chronic liver in these in the a of be for WD patients with or to also be for WD WD be in the diagnosis of patients with liver disease or of WD be in with hepatic with in or and of to of of with WD be for WD to liver and of neurological copper, ceruloplasmin, liver function including and and of the for and and abnormal liver liver to the for ATP7B or studies be and be as be for than as patients by for Wilson disease in or of a with diagnosis of is in the is the most by and is in 2-5 to or or including liver ceruloplasmin, copper liver when of in or from of with WD, of of is can be of with WD be for WD the first the of WD, was treatment for controlled were when treatment for WD from the of to the more are studies of and the use was by the of the drug were formal studies for time were when these treatment was first for patients were to disease. with the in for WD, a was in by the that significant and be by the treatment of The of to was by the of some patients to was developed and for patients developed to was developed as was which was by for copper in the of treatment for WD liver which the hepatic in WD, is for or In the approach to treatment is on is disease or or evidence of or or the is to the of in the of and the of are studies in which approach has been The recommended treatment of patients or with disease is with are some treatment with be for some The treatment experience is with is more of for that the of in patients with or hepatic disease. to the use of were and many experience with in which is in with a has a in copper and excess are some of the use of and as and studies are to is than with of the use of as an for the treatment of WD suggest that drug be as for patients with neurological disease or typically in of of or can be for be with of a or with from the Failure to with has to and liver the liver for of for as as for are in was as the first for WD in was as a of is the amino acid with it has a which functions as the copper is as and with is an the which to with is is at a of by The of in WD is to the excretion of also by in with also with and has some is a of is to and has been as an in is absorbed from the with a for by an to the followed by is with a is decreased by is at of to is in the it or to than of excretion is the The excretion of is on the of is and or can be in the the drug has been The use of was for the treatment of and studies to the of as treatment for of has been reported in of with the of In a on for WD, mainly with where were patients with liver the time for evidence of of function and in as and is typically the first of can the first of Failure to with has to significant of liver disease and liver in of in or liver use is with the drug to be in of by and or and the first be the of a of by or the of other in the for which of be a by and and with of typically for WD, or reported in the and and or and the drug it has been of A and has been has been reported in patients with reduced of and of be by with by every to a of in is in in the is to the and in or is to or to is it from of treatment with is that the of or the of chronic the in some patients with hepatic as function in to In in in patients with be a of copper and is with and of treatment is by copper excretion on This is treatment and at that chronic copper excretion in the of on In of copper of the copper with of copper excretion to or and excess copper In with to copper is or with are or or also known by is of a of with a from and copper is by a with the in a was in as an to the of is absorbed from the and is absorbed is and of the and of the in the The is a less than The amounts of copper, and in with the of in the copper excretion by the is a of copper than is and can for small and of is treatment for and is in patients are of or of disease of treatment with has been reported less than with has also been to be for with liver disease at the has been reported a drug was in has been also and of and be the with is A be a of and copper also been reported in some WD patients with these patients were with the of when is is In to when is for and treatment with Use in patients with biliary that of and evidence that copper by can in in of patients with WD, to that for are in or with or for In the is established, the is to the in or be or it to is are for at which is a problem for patients to of treatment is by copper excretion on This in the of on treatment be when treatment is first of copper of the copper with of copper excretion to or and excess copper In with to copper is or with are or was first to WD by in in the of is from that of and with the of copper from the a protein that is an of has for copper than for and copper in the and into the portal circulation. the copper is absorbed is into the as enterocytes are in copper also the from and treatment can a for copper and also by of hepatocellular has is the problem and be on the has been reported when was and was in and on function with chronic in or evidence of is with is for patients with function is is for it has been as most for or to be as of large studies of with WD A with and was with a other in and in treatment with or in which the and the are at the has been reported in is in of and is in with the be and it has to be at to be The a with to to and be more than with in the is in and the is for of with with and of can be to for of treatment with is by and and by excretion of copper, which be less than on of copper of the copper with excretion of be from time to time to mainly a role as and hepatic been to be in when was to the treatment has been reported studies been of with with of copper and be at in the first of in copper the of the disease and disease dietary is recommended as with a is for or into the copper be for copper in to be A be the copper of the is with copper it is important to the of for or Copper or be to or or is a which by with of copper with and copper from copper from at it an copper which is deposited in the an in the and it is it neurological and copper which neurological also has to or patients treatment with a as or with is in disease or for the of treatment with a patients be on a of the or to treatment with In patients been for They be with and hepatic copper in the and copper in the of on The of treatment with that it is more for copper than or and is with studies the of in treatment of patients with hepatic WD are and are for a treatment be treatment of hepatic treatment for patients a or be intake of and with of copper, the first of treatment of patients or on can be with a or with be with chronic liver typically with been with a or The of treatment be the in with of in to the and the of A is or in by as the first and and or in by as the and This is an patients and be to a be to or as This treatment some with liver to WD liver which is To which patients with hepatic liver developed a and of time patients with a of 7 or in of patients with been for and with liver to be can be and and or or the from was to patients with liver to WD and the for The be in In treatment be the of for patients with of treatment has in liver to the and and been with for the and The of a has been in of the of has it to is from the of these in the at The of is of be reduced to the for the to is a be on the of of the be the drug is into and the is known the of and in Liver is the for with WD with liver and is for patients with WD with liver disease to Liver the hepatic metabolic of WD and to of copper liver from and to in the the of patients liver for WD organs, can be is when the is a for for liver for patients with to neurological disease. for or which liver are also a of other for disease liver on the of these patients are Liver is recommended as a treatment for WD the liver disease is by in most of these and with liver are patients with neurological or disease to WD and also with to liver with liver to WD be for and with liver with to treatment be for liver for WD be is for and is and be a liver has been The of treatment is to and with and in a The of of patients at a it be a is the of for of or of and in of with for evidence of liver disease and neurological for be is a of or in a in were the of disease. patients on be on A also for liver including of hepatic function and of copper copper and the copper provide the to treatment of copper excretion on copper and is for or copper excretion of for patients on it be more than patients on for copper suggest to and hepatic for copper excretion for patients on treatment can also and is accompanied by for of and as as can also be in these or are also for copper these in patients can also be by or which be on the of The be in patients on and a be to copper and ceruloplasmin, liver and and for on and be at a and been on treatment The excretion of copper on be or more are on or of is The copper be in of and in of This guideline was in with the Practice Guidelines Committee of the AASLD which review of the of the AASLD Practice Guidelines Committee and

BACKGROUND: Data on the effect of initial combination therapy with ambrisentan and tadalafil on long-term outcomes in patients with pulmonary arterial hypertension are scarce. METHODS: In this event-driven, double-blind study, we randomly assigned, in a 2:1:1 ratio, participants with World Health Organization functional class II or III symptoms of pulmonary arterial hypertension who had not previously received treatment to receive initial combination therapy with 10 mg of ambrisentan plus 40 mg of tadalafil (combination-therapy group), 10 mg of ambrisentan plus placebo (ambrisentan-monotherapy group), or 40 mg of tadalafil plus placebo (tadalafil-monotherapy group), all administered once daily. The primary end point in a time-to-event analysis was the first event of clinical failure, which was defined as the first occurrence of a composite of death, hospitalization for worsening pulmonary arterial hypertension, disease progression, or unsatisfactory long-term clinical response. RESULTS: The primary analysis included 500 participants; 253 were assigned to the combination-therapy group, 126 to the ambrisentan-monotherapy group, and 121 to the tadalafil-monotherapy group. A primary end-point event occurred in 18%, 34%, and 28% of the participants in these groups, respectively, and in 31% of the pooled-monotherapy group (the two monotherapy groups combined). The hazard ratio for the primary end point in the combination-therapy group versus the pooled-monotherapy group was 0.50 (95% confidence interval [CI], 0.35 to 0.72; P<0.001). At week 24, the combination-therapy group had greater reductions from baseline in N-terminal pro-brain natriuretic peptide levels than did the pooled-monotherapy group (mean change, -67.2% vs. -50.4%; P<0.001), as well as a higher percentage of patients with a satisfactory clinical response (39% vs. 29%; odds ratio, 1.56 [95% CI, 1.05 to 2.32]; P=0.03) and a greater improvement in the 6-minute walk distance (median change from baseline, 48.98 m vs. 23.80 m; P<0.001). The adverse events that occurred more frequently in the combination-therapy group than in either monotherapy group included peripheral edema, headache, nasal congestion, and anemia. CONCLUSIONS: Among participants with pulmonary arterial hypertension who had not received previous treatment, initial combination therapy with ambrisentan and tadalafil resulted in a significantly lower risk of clinical-failure events than the risk with ambrisentan or tadalafil monotherapy. (Funded by Gilead Sciences and GlaxoSmithKline; AMBITION ClinicalTrials.gov number, NCT01178073.).

BACKGROUND: We conducted a randomized trial of prophylactic cranial irradiation in patients with extensive small-cell lung cancer who had had a response to chemotherapy. METHODS: Patients between the ages of 18 and 75 years with extensive small-cell lung cancer were randomly assigned to undergo prophylactic cranial irradiation (irradiation group) or receive no further therapy (control group). The primary end point was the time to symptomatic brain metastases. Computed tomography or magnetic resonance imaging of the brain was performed when any predefined key symptom suggestive of brain metastases was present. RESULTS: The two groups (each with 143 patients) were well balanced regarding baseline characteristics. Patients in the irradiation group had a lower risk of symptomatic brain metastases (hazard ratio, 0.27; 95% confidence interval [CI], 0.16 to 0.44; P<0.001). The cumulative risk of brain metastases within 1 year was 14.6% in the irradiation group (95% CI, 8.3 to 20.9) and 40.4% in the control group (95% CI, 32.1 to 48.6). Irradiation was associated with an increase in median disease-free survival from 12.0 weeks to 14.7 weeks and in median overall survival from 5.4 months to 6.7 months after randomization. The 1-year survival rate was 27.1% (95% CI, 19.4 to 35.5) in the irradiation group and 13.3% (95% CI, 8.1 to 19.9) in the control group. Irradiation had side effects but did not have a clinically significant effect on global health status. CONCLUSIONS: Prophylactic cranial irradiation reduces the incidence of symptomatic brain metastases and prolongs disease-free and overall survival. (ClinicalTrials.gov number, NCT00016211 [ClinicalTrials.gov].).

BACKGROUND: Multiple myeloma cells uniformly overexpress CD38. We studied daratumumab, a CD38-targeting, human IgG1κ monoclonal antibody, in a phase 1-2 trial involving patients with relapsed myeloma or relapsed myeloma that was refractory to two or more prior lines of therapy. METHODS: In part 1, the dose-escalation phase, we administered daratumumab at doses of 0.005 to 24 mg per kilogram of body weight. In part 2, the dose-expansion phase, 30 patients received 8 mg per kilogram of daratumumab and 42 received 16 mg per kilogram, administered once weekly (8 doses), twice monthly (8 doses), and monthly for up to 24 months. End points included safety, efficacy, and pharmacokinetics. RESULTS: No maximum tolerated dose was identified in part 1. In part 2, the median time since diagnosis was 5.7 years. Patients had received a median of four prior treatments; 79% of the patients had disease that was refractory to the last therapy received (64% had disease refractory to proteasome inhibitors and immunomodulatory drugs and 64% had disease refractory to bortezomib and lenalidomide), and 76% had received autologous stem-cell transplants. Infusion-related reactions in part 2 were mild (71% of patients had an event of any grade, and 1% had an event of grade 3), with no dose-dependent adverse events. The most common adverse events of grade 3 or 4 (in ≥ 5% of patients) were pneumonia and thrombocytopenia. The overall response rate was 36% in the cohort that received 16 mg per kilogram (15 patients had a partial response or better, including 2 with a complete response and 2 with a very good partial response) and 10% in the cohort that received 8 mg per kilogram (3 had a partial response). In the cohort that received 16 mg per kilogram, the median progression-free survival was 5.6 months (95% confidence interval [CI], 4.2 to 8.1), and 65% (95% CI, 28 to 86) of the patients who had a response did not have progression at 12 months. CONCLUSIONS: Daratumumab monotherapy had a favorable safety profile and encouraging efficacy in patients with heavily pretreated and refractory myeloma. (Funded by Janssen Research and Development and Genmab; ClinicalTrials.gov number, NCT00574288.).